Background Since the release of the first global hepatitis elimination targets in 2016, and
until the COVID-19 pandemic started in early 2020, many countries and territories were …

Background Since the release of the first global hepatitis elimination targets in 2016, and
until the COVID-19 pandemic started in early 2020, many countries and territories were …

Summary Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity
and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct …

Summary Background The 69th World Health Assembly approved the Global Health Sector
Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality …

Abstract Background & Aims Introduction of highly efficacious pan‐genotypic therapies for
hepatitis C virus (HCV) infection has made the elimination of the disease an attainable goal …

ABSTRACT BACKGROUND & AIMS Elimination of HCV by 2030, as defined by the World
Health Organization (WHO), is attainable with the availability of highly efficacious therapies …

Background The revolution in hepatitis C virus (HCV) treatment through the development of
direct-acting antivirals (DAAs) has generated international interest in the global elimination …

The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV)
infections change over time making it difficult to compare reported estimates from different …

Background Treatment for infection with hepatitis C virus (HCV) during pregnancy has not
yet been approved; however, interventions specifically targeting women, especially those of …

Background & Aims Coronavirus disease 2019 (COVID-19) has placed a significant strain
on national healthcare systems at a critical moment in the context of hepatitis elimination …